03:20 PM EST, 11/06/2025 (MT Newswires) -- Neurogene ( NGNE ) said Thursday that the first patient has been dosed in its registrational trial evaluating NGN-401, a gene therapy candidate for Rett syndrome.

The company said it expects to complete enrollment in three to six months.

The trial is designed to support a future Biologics License Application submission to the FDA and will evaluate NGN-401 in 20 female participants aged at least three years old, the company added.

Shares of the company were down 3.8% in recent trading Thursday.

Price: 26.70, Change: -1.02, Percent Change: -3.68